COMMUNIQUÉS West-GlobeNewswire

-
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
16/06/2025 -
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
16/06/2025 -
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
16/06/2025 -
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
16/06/2025 -
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
16/06/2025 -
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
16/06/2025 -
Aurora Spine Surpasses 1,500 Successful Surgeries Using DEXA-C™
16/06/2025 -
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
16/06/2025 -
Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology
16/06/2025 -
Transactions under Novonesis’ share buyback program
16/06/2025 -
FOXO TECHNOLOGIES INC. CREATES ACQUISITION VEHICLE AND APPOINTS NEW INTERIM CFO
16/06/2025 -
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
16/06/2025 -
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
16/06/2025 -
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
16/06/2025 -
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
16/06/2025 -
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
16/06/2025 -
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
16/06/2025 -
Extendicare Announces June 2025 Dividend of C$0.042 per Share
16/06/2025 -
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
16/06/2025
Pages